Enanta Pharmaceuticals (ENTA) Net Equity Issued and Repurchased (2018 - 2019)

Enanta Pharmaceuticals (ENTA) posted Net Equity Issued and Repurchased of $709000.0 for Q3 2019, up 38.48% on a QoQ basis from $512000.0 in Q2 2019, and down 32.6% year-over-year from $1.1 million in Q3 2018.

Enanta Pharmaceuticals (ENTA) Net Equity Issued and Repurchased (2018 - 2019) Analysis & Trends

Enanta Pharmaceuticals' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $709000.0 for Q3 2019.

  • Quarterly Net Equity Issued and Repurchased fell 32.6% year-over-year to $709000.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $5.3 million (changed N/A YoY) and the FY2021 annual result came in at $3.6 million, down 65.52% from the prior year.
  • Net Equity Issued and Repurchased was $709000.0 for Q3 2019 at Enanta Pharmaceuticals, up from $512000.0 in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $3.0 million in Q2 2018 and bottomed at $512000.0 in Q2 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Enanta Pharmaceuticals 376.07 Mn 212.29 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2019 709,000.00
Sep 30, 2019 709,000.00
Jun 30, 2019 512,000.00
Jun 30, 2019 512,000.00
Sep 30, 2018 1.05 Mn
Sep 30, 2018 1.05 Mn
Jun 30, 2018 2.99 Mn
Jun 30, 2018 2.99 Mn